SCHEINER, BERNHARD

SCHEINER, BERNHARD  

Mostra records
Risultati 1 - 15 di 15 (tempo di esecuzione: 0.031 secondi).
Titolo Data di pubblicazione Autore(i) File
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 1-gen-2023 Pinato, D. J.; Li, X.; Mishra-Kalyani, P.; D'Alessio, A.; Fulgenzi, C. A. M.; Scheiner, B.; Pinter, M.; Wei, G.; Schneider, J.; Rivera, D. R.; Pazdur, R.; Theoret, M. R.; Casak, S.; Lemery, S.; Fashoyin-Aje, L.; Cortellini, A.; Pelosof, L.
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 1-gen-2023 Semmler, G.; Scheiner, B.; Balcar, L.; Paternostro, R.; Simbrunner, B.; Pinter, M.; Trauner, M.; Bofillroig, M.; Meyer, E. L.; Hofer, B. S.; Mandorfer, M.; Pinato, D. J.; Zauner, C.; Reiberger, T.; Funk, G. -C.
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 1-gen-2023 Scheiner, B.; Roessler, D.; Phen, S.; Lim, M.; Pomej, K.; Pressiani, T.; Cammarota, A.; Frundt, T. W.; von Felden, J.; Schulze, K.; Himmelsbach, V.; Finkelmeier, F.; Deibel, A.; Siebenhuner, A. R.; Shmanko, K.; Radu, P.; Schwacha-Eipper, B.; Ebert, M. P.; Teufel, A.; Djanani, A.; Hucke, F.; Balcar, L.; Philipp, A. B.; Hsiehchen, D.; Venerito, M.; Sinner, F.; Trauner, M.; D'Alessio, A.; Fulgenzi, C. A. M.; Pinato, D. J.; Peck-Radosavljevic, M.; Dufour, J. -F.; Weinmann, A.; Kremer, A. E.; Singal, A. G.; De Toni, E. N.; Rimassa, L.; Pinter, M.
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 1-gen-2024 Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia Angela Maria; Battaglia, Salvatore; Enea, Marco; Scheiner, Bernhard; D'Alessio, Antonio; Manfredi, Giulia F.; Stefanini, Bernardo; Nishida, Naoshi; Galle, Peter R.; Schulze, Kornelius; Wege, Henning; Ciccia, Roberta; Hsu, Wei-Fan; Vivaldi, Caterina; Wietharn, Brooke; Lin, Ryan Po-Ting; Pirozzi, Angelo; Pressiani, Tiziana; Dalbeni, Andrea; Natola, Leonardo A.; Auriemma, Alessandra; Rigamonti, Cristina; Burlone, Michela; Parisi, Alessandro; Huang, Yi-Hsiang; Lee, Pei-Chang; Ang, Celina; Marron, Thomas U.; Pinter, Matthias; Cheon, Jaekyung; Phen, Samuel; Singal, Amit G; Gampa, Anuhya; Pillai, Anjana; Roehlen, Natascha; Thimme, Robert; Vogel, Arndt; Soror, Noha; Ulahannan, Susanna; Sharma, Rohini; Sacerdoti, David; Pirisi, Mario; Rimassa, Lorenza; Lin, Chun-Yen; Saeed, Anwaar; Masi, Gianluca; Schönlein, Martin; von Felden, Johann; Kudo, Masatoshi; Cortellini, Alessio; Chon, Hong Jae; Cammà, Calogero; Pinato, David James
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 1-gen-2023 Pinter, Matthias; Scheiner, Bernhard; Pinato, David J
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 1-gen-2023 Vithayathil, M.; D'Alessio, A.; Fulgenzi, C. A. M.; Nishida, N.; Schonlein, M.; von Felden, J.; Schulze, K.; Wege, H.; Saeed, A.; Wietharn, B.; Hildebrand, H.; Wu, L.; Ang, C.; Marron, T. U.; Weinmann, A.; Galle, P. R.; Bettinger, D.; Bengsch, B.; Vogel, A.; Balcar, L.; Scheiner, B.; Lee, P. -C.; Huang, Y. -H.; Amara, S.; Muzaffar, M.; Naqash, A. R.; Cammarota, A.; Zanuso, V.; Pressiani, T.; Pinter, M.; Cortellini, A.; Kudo, M.; Rimassa, L.; Pinato, D. J.; Sharma, R.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 1-gen-2022 Vithayathil, M.; D'Alessio, A.; Fulgenzi, C. A. M.; Nishida, N.; Schonlein, M.; von Felden, J.; Schulze, K.; Wege, H.; Saeed, A.; Wietharn, B.; Hildebrand, H.; Wu, L.; Ang, C.; Marron, T. U.; Weinmann, A.; Galle, P. R.; Bettinger, D.; Bengsch, B.; Vogel, A.; Balcar, L.; Scheiner, B.; Lee, P. -C.; Huang, Y. -H.; Amara, S.; Muzaffar, M.; Naqash, A. R.; Cammarota, A.; Personeni, N.; Pressiani, T.; Pinter, M.; Cortellini, A.; Kudo, M.; Rimassa, L.; Pinato, D. J.; Sharma, R.
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 1-gen-2022 Wu, Y. L.; Fulgenzi, C. A. M.; D'Alessio, A.; Cheon, J.; Nishida, N.; Saeed, A.; Wietharn, B.; Cammarota, A.; Pressiani, T.; Personeni, N.; Pinter, M.; Scheiner, B.; Balcar, L.; Huang, Y. -H.; Phen, S.; Naqash, A. R.; Vivaldi, C.; Salani, F.; Masi, G.; Bettinger, D.; Vogel, A.; Schonlein, M.; von Felden, J.; Schulze, K.; Wege, H.; Galle, P. R.; Kudo, M.; Rimassa, L.; Singal, A. G.; Sharma, R.; Cortellini, A.; Gaillard, V. E.; Chon, H. J.; Pinato, D. J.; Ang, C.
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 1-gen-2023 Wu, Y. L.; van Hyfte, G.; Ozbek, U.; Reincke, M.; Gampa, A.; Mohamed, Y. I.; Nishida, N.; Wietharn, B.; Amara, S.; Lee, P. -C.; Scheiner, B.; Balcar, L.; Pinter, M.; Vogel, A.; Weinmann, A.; Saeed, A.; Pillai, A.; Rimassa, L.; Naqash, A. R.; Muzaffar, M.; Huang, Y. -H.; Kaseb, A. O.; Kudo, M.; Pinato, D. J.; Ang, C.
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 1-gen-2023 Fessas, P.; Scheiner, B.; D'Alessio, A.; M Fulgenzi, C. A.; Korolewicz, J.; Ward, C.; Tait, P.; Thomas, R.; Cortellini, A.; Sharma, R.; Pinato, D. J.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 1-gen-2022 D'Alessio, A.; Fulgenzi, C. A. M.; Nishida, N.; Schonlein, M.; von Felden, J.; Schulze, K.; Wege, H.; Gaillard, V. E.; Saeed, A.; Wietharn, B.; Hildebrand, H.; Wu, L.; Ang, C.; Marron, T. U.; Weinmann, A.; Galle, P. R.; Bettinger, D.; Bengsch, B.; Vogel, A.; Balcar, L.; Scheiner, B.; Lee, P. -C.; Huang, Y. -H.; Amara, S.; Muzaffar, M.; Naqash, A. R.; Cammarota, A.; Personeni, N.; Pressiani, T.; Sharma, R.; Pinter, M.; Cortellini, A.; Kudo, M.; Rimassa, L.; Pinato, D. J.
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 1-gen-2023 Talbot, T.; D'Alessio, A.; Pinter, M.; Balcar, L.; Scheiner, B.; Marron, T. U.; Jun, T.; Dharmapuri, S.; Ang, C.; Saeed, A.; Hildebrand, H.; Muzaffar, M.; Fulgenzi, C. A. M.; Amara, S.; Naqash, A. R.; Gampa, A.; Pillai, A.; Wang, Y.; Khan, U.; Lee, P. -C.; Huang, Y. -H.; Bengsch, B.; Bettinger, D.; Mohamed, Y. I.; Kaseb, A.; Pressiani, T.; Personeni, N.; Rimassa, L.; Nishida, N.; Kudo, M.; Weinmann, A.; Galle, P. R.; Muhammed, A.; Cortellini, A.; Vogel, A.; Pinato, D. J.
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 1-gen-2022 Fulgenzi, C. A. M.; Cheon, J.; D'Alessio, A.; Nishida, N.; Ang, C.; Marron, T. U.; Wu, L.; Saeed, A.; Wietharn, B.; Cammarota, A.; Pressiani, T.; Personeni, N.; Pinter, M.; Scheiner, B.; Balcar, L.; Napolitano, A.; Huang, Y. -H.; Phen, S.; Naqash, A. R.; Vivaldi, C.; Salani, F.; Masi, G.; Bettinger, D.; Vogel, A.; Schonlein, M.; von Felden, J.; Schulze, K.; Wege, H.; Galle, P. R.; Kudo, M.; Rimassa, L.; Singal, A. G.; Sharma, R.; Cortellini, A.; Gaillard, V. E.; Chon, H. J.; Pinato, D. J.
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 1-gen-2022 Muhammed, A.; Fulgenzi, C. A. M.; Dharmapuri, S.; Pinter, M.; Balcar, L.; Scheiner, B.; Marron, T. U.; Jun, T.; Saeed, A.; Hildebrand, H.; Muzaffar, M.; Navaid, M.; Naqash, A. R.; Gampa, A.; Ozbek, U.; Lin, J. -Y.; Perone, Y.; Vincenzi, B.; Silletta, M.; Pillai, A.; Wang, Y.; Khan, U.; Huang, Y. -H.; Bettinger, D.; Abugabal, Y. I.; Kaseb, A.; Pressiani, T.; Personeni, N.; Rimassa, L.; Nishida, N.; Tommaso, L. D.; Kudo, M.; Vogel, A.; Mauri, F. A.; Cortellini, A.; Sharma, R.; D'Alessio, A.; Ang, C.; Pinato, D. J.
Tumor-infiltrating Neutrophils: Gatekeepers in Liver Cancer Immune Control 1-gen-2023 Scheiner, B.; Pinato, D. J.